Zylox-Tonbridge Med Tech Co (2190) Fair Value & Analysis
Healthcare · HK · Market cap HK$6.3B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 3 days ago
Fair value updated Aug 13, 2026, revised from HK$13.57 to HK$13.31 (−1.9%) since Aug 5, 2026. Share price −3.1% over the past month.
A strong business, but screening 31% overvalued on our models.
What matters now
- A high-quality business (quality 80/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (HK$16.58). The favourable scenario is already priced in.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$7.48 – HK$58.94 · fair‑value band HK$10.38 – HK$16.58 · the HK$19.36 price screens above the HK$13.31 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Zylox-Tonbridge Med Tech Co (2190) currently trades at HK$19.36, while our model-based Fair Value estimate is HK$13.31, implying the stock looks roughly 31.3% overvalued today. The Quality Score stands at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Zylox-Tonbridge Med Tech Co generated revenue of HK$1.1B at a net margin of 23.1%. Revenue grew 38.2% year over year. It earns a return on equity of 7.7%. The balance sheet holds a net cash position of HK$516M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$10.38 (bear case) to HK$16.58 (bull case); at HK$19.36, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 13% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -31%, 2190 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (HK$35.02) versus Dividend Discount (HK$1.49). Highest evidence: Growth DCF (80).
Notify me when 2190 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 78 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People's Republic of China and internationally.
Full company description
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People's Republic of China and internationally. It offers a neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and intracranial access devices. The company's peripheral-vascular interventional product portfolio includes stents, balloons, catheters, and filters, as well as covers hemodialysis access, arterial, venous, peripheral embolization intervention, and other intervention products. In addition, the company provides technical consultation and services, as well as imports materials. It serves patients and physicians. The company was formerly known as Zhejiang Zylox Medical Device Co., Ltd. and changed its name to Zylox-Tonbridge Medical Technology Co., Ltd. in March 2021. Zylox-Tonbridge Medical Technology Co., Ltd. was incorporated in 2012 and is headquartered in Hangzhou, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zylox-Tonbridge Med Tech Co reported revenue of HK$1.1B in FY2025 versus HK$178M in FY2021, a compound +56.1%/yr. Reported net income was HK$244M in FY2025.
2190 screens 31% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 350 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
Compare Zylox-Tonbridge Med Tech Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zylox-Tonbridge Med Tech Co (2190) overvalued or undervalued?
What is the fair value of 2190?
What is the quality score of 2190?
What is the revenue of Zylox-Tonbridge Med Tech Co (2190)?
What is the net profit margin of 2190?
Does Zylox-Tonbridge Med Tech Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zylox-Tonbridge Med Tech Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.